| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac409458365ff9d5dc07bf78b39ea951 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0087
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-71 |
| filingDate |
2018-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f348239a53aee36918562afa5d46ede6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88dc4ba2ae4d722b755c65ae7da5bae3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f3679b2fbeb76c780073c72f3a74732 |
| publicationDate |
2020-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3692057-A1 |
| titleOfInvention |
Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
| abstract |
The present invention provides modified EGFR peptides useful in genetically engineered cells to enable selection and enrichment of these cells expressing the modified EGFR peptide. For example, the isolation of genetically modified cells expressing a modified EGFR peptide may allow selection of cells that coexpress a chimeric antigen receptor or an exogenous T cell receptor. In cases where the genetically modified cells have undesirable effects when administered to a subject, the modified EGFR further finds use as a suicide gene when administering an anti-EGFR antibody, thereby leads to a depletion of genetically modified cells. The present invention also relates to plasmids and viral vectors comprising a nucleic acid sequence encoding the modified EGFR peptides, and methods of administering compositions comprising the modified EGFR peptides to subjects to reduce symptoms. , progression or onset of a disease, such as cancer. |
| priorityDate |
2017-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |